Intelligent Bio Solutions Inc. filings document a medical technology issuer commercializing rapid, non-invasive fingerprint sweat drug screening and reporting through periodic material-event disclosures. Recent 8-Ks cover operating results, preliminary revenue information, Regulation FD presentations, clinical study program updates tied to the Intelligent Fingerprinting Drug Screening System, and manufacturing disclosures for readers and lateral-flow test strips.
The filing record also includes capital-structure and governance subjects, including common stock issued through warrant exercises and an at-the-market offering agreement, restricted stock awards under the 2019 Long Term Incentive Plan and Australian Sub-Plan, and Nasdaq Capital Market bid-price compliance notices. These disclosures frame the company's product commercialization, regulatory pathway, equity compensation, share count and listing-status matters.
Intelligent Bio Solutions Inc. proxy materials disclose governance and compensation program details including an Insider Trading Policy that forbids hedging transactions by directors, officers and employees and requires compliance with applicable securities laws. The company implemented a Dodd-Frank restatement recoupment (clawback) policy effective October 2, 2023 to recoup erroneously awarded incentive compensation tied to a restatement over a defined lookback period. The filing shows an equity compensation plan with 1,192,655 shares referenced and plan provisions covering stock options, SARs, restricted stock, RSUs, transfer limits, typical vesting practices and a maximum 10-year option term (five years for >10% holders). A reverse stock split amendment is being recommended by the Board for stockholder approval. The largest disclosed shareholder is Alyeska Master Fund, LP with 927,292 shares (9.99%). Executive and director compensation snippets appear (e.g., Spiro Sakiris totals and director fees) and the Plan notes that shares to be issued are not registered under the Securities Act as of the Effective Date.
Intelligent Bio Solutions Inc. proxy materials disclose governance and compensation program details including an Insider Trading Policy that forbids hedging transactions by directors, officers and employees and requires compliance with applicable securities laws. The company implemented a Dodd-Frank restatement recoupment (clawback) policy effective October 2, 2023 to recoup erroneously awarded incentive compensation tied to a restatement over a defined lookback period. The filing shows an equity compensation plan with 1,192,655 shares referenced and plan provisions covering stock options, SARs, restricted stock, RSUs, transfer limits, typical vesting practices and a maximum 10-year option term (five years for >10% holders). A reverse stock split amendment is being recommended by the Board for stockholder approval. The largest disclosed shareholder is Alyeska Master Fund, LP with 927,292 shares (9.99%). Executive and director compensation snippets appear (e.g., Spiro Sakiris totals and director fees) and the Plan notes that shares to be issued are not registered under the Securities Act as of the Effective Date.
Intelligent Bio Solutions Inc. is registering up to $1,211,174 of common stock under an at-the-market offering program with Ladenburg Thalmann. The company may sell shares from time to time on Nasdaq, paying Ladenburg a 3% commission, and plans to use net proceeds of up to about $1.064 million primarily for working capital and general corporate purposes.
As of September 17, 2025, common stock outstanding was 9,077,326 shares, with an illustrative post-offering total of 9,936,314 shares if 858,988 shares are sold at $1.41, which would dilute new investors. The company reported cash and cash equivalents of $1,019,909 as of June 30, 2025 and its auditor raised substantial doubt about its ability to continue as a going concern.
Recent FDA interactions add regulatory uncertainty: after a 510(k) submission for its Intelligent Fingerprinting System, the FDA requested additional information on September 12, 2025 that will require a new 510(k) filing, and the company expects to update investors with a revised clearance timeline.
Intelligent Bio Solutions Inc. is registering up to $1,211,174 of common stock under an at-the-market offering program with Ladenburg Thalmann. The company may sell shares from time to time on Nasdaq, paying Ladenburg a 3% commission, and plans to use net proceeds of up to about $1.064 million primarily for working capital and general corporate purposes.
As of September 17, 2025, common stock outstanding was 9,077,326 shares, with an illustrative post-offering total of 9,936,314 shares if 858,988 shares are sold at $1.41, which would dilute new investors. The company reported cash and cash equivalents of $1,019,909 as of June 30, 2025 and its auditor raised substantial doubt about its ability to continue as a going concern.
Recent FDA interactions add regulatory uncertainty: after a 510(k) submission for its Intelligent Fingerprinting System, the FDA requested additional information on September 12, 2025 that will require a new 510(k) filing, and the company expects to update investors with a revised clearance timeline.
Intelligent Bio Solutions Inc. reported that the FDA has requested additional information on its Intelligent Fingerprinting Drug Screening System, requiring the company to submit a new 510(k) notification. The FDA’s requests were communicated in a letter dated September 12, 2025. The company plans to provide an investor update within the next ten days to outline a revised timeline for potential FDA 510(k) clearance of the drug screening system.
Intelligent Bio Solutions Inc. preliminary proxy excerpt discloses governance and compensation policies for executives and directors. The company has an Insider Trading Policy that prohibits hedging transactions and requires compliance with securities laws. A clawback/recoupment policy applies to incentive-based compensation for executive officers in the event of a required financial restatement, covering awards received after October 2, 2023, and looking back three completed fiscal years plus certain transition periods.
The document shows director and named executive officer compensation items and totals for 2024 and 2025 (examples: Spiro Sakiris total compensation figures of $446,622 in 2024 and $363,532 in 2025; other individual director fees like $51,250, $50,625, $55,625). It outlines an equity compensation plan (2019 Plan) with current shares reserved and available: 7,154,982 securities reserved for outstanding options/warrants/rights, 100,000,000 shares authorized, and available shares under the plan of 1,192,655 (if Proposal 3 not approved) or 1,687,655 (if approved). A proposed Reverse Stock Split amendment is described as subject to shareholder approval, with the Board to fix the ratio within the approved range. A 9.99% holder is identified: Alyeska Master Fund, LP (921,825 shares).
The prospectus fragment for Intelligent Bio Solutions Inc. (INBS) discloses that the Series J Warrants have an initial exercise price of $1.90 per share, expire 5.5 years after issuance, and would convert into up to 4,046,456 shares of common stock if exercised. Exercise is conditioned on the Company receiving stockholder approval. The filing also lists key executives and directors, including CEO Harry Simeonidis and CFO Spiro Sakiris. The provided text appears partial and lacks broader financial data.
The prospectus fragment for Intelligent Bio Solutions Inc. (INBS) discloses that the Series J Warrants have an initial exercise price of $1.90 per share, expire 5.5 years after issuance, and would convert into up to 4,046,456 shares of common stock if exercised. Exercise is conditioned on the Company receiving stockholder approval. The filing also lists key executives and directors, including CEO Harry Simeonidis and CFO Spiro Sakiris. The provided text appears partial and lacks broader financial data.
Intelligent Bio Solutions, Inc. filed an S-3 shelf registration describing ownership and disclosure exhibits. The filing lists significant holders including Alyeska Master Fund, LP with 1,758,240 shares (16.99%), CVI Investments, Inc. with 1,421,556 shares (13.74%), and Warberg WF XII LP with 1,279,120 shares (12.65%). Several other institutional and insider holdings are reported with percentages or ‘‘*’’ denoting de minimis amounts. The filing references a Form 8-A originally filed December 22, 2020, and identifies SEC registration fee of $919.16, accounting fees of $5,000.00, and a total listed as $25,919.16. The document is signed by the CEO, CFO, Chairman, and multiple directors with signature dates of August 22, 2025.
Intelligent Bio Solutions Inc. filed a current report to disclose that it issued a press release on August 15, 2025 announcing its financial results for the three months and full fiscal year ended June 30, 2025. The press release is attached as Exhibit 99.1.
The company states that the information in this report and the exhibit is being furnished, not filed, so it is not subject to certain liability provisions under U.S. securities laws and will not be incorporated into other filings unless specifically referenced.
Intelligent Bio Solutions Inc. (INBS) reported operating results and disclosures in its Form 10-K showing continued commercial rollout of its Intelligent Fingerprinting (IFP) products and persistent losses that raise near-term financing risk. The company installed over 1,000 IFP readers, added 115 new customer accounts, launched localized websites in Arabic, Italian and Spanish, was granted a U.S. patent for its drug screening cartridge, and completed a pharmacokinetic study supporting a 510(k) submission (Dec 2024) for codeine detection.
Financially, revenue line items include reader sales of $711,737 (FY2025) with GAAP gross profit of $1,246,859. The company recorded a net loss of $10,604,886, shareholders' equity of $2,813,824, a working capital deficit of $1,212,419, and an accumulated deficit of $62,533,065. Management discloses an explanatory audit paragraph on its ability to continue as a going concern and states it will need to raise additional capital within twelve months.
Intelligent Bio Solutions, Inc. (INBS) filed a Form D reporting a Regulation D, Rule 506(b) offering in which the issuer raised $3,839,356. The filing shows the total amount offered equaled the amount sold, with